| Scrip Code | 524372 |
|---|---|
| NSE Symbol | ORCHPHARMA |
| MSEI Symbol | NOTLISTED |
| ISIN | INE191A01027 |
| Name of company | Orchid Pharma Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 11-11-2025 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 05-11-2025 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Second quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceutical |
| Start date and time of board meeting | 11-11-2025 12:00:00 |
| End date and time of board meeting | 11-11-2025 15:00:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 11-11-2024 |
| Indicate Company website link for updated RPT policy of the Company | www.orchidpharma.com |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 1 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| Not Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period. | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 19,352.42 | 36,645.30 | |
| Other income | 1,542.52 | 3,135.56 | |
| Total income | 20,894.94 | 39,780.86 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 11,226.77 | 22,242.51 |
| (b) | Purchases of stock-in-trade | 17.34 | 96.13 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 2,006.54 | 798.55 |
| (d) | Employee benefit expense | 2,404.69 | 4,565.98 |
| (e) | Finance costs | 373.23 | 698.98 |
| (f) | Depreciation, depletion and amortisation expense | 879.13 | 1,744.54 |
| (f) | Other Expenses | ||
| 1 | Other expenses | 3,764.13 | 7,591.32 |
| Total other expenses | 3,764.13 | 7,591.32 | |
| Total expenses | 20,671.83 | 37,738.01 | |
| 3 | Total profit before exceptional items and tax | 223.11 | 2,042.85 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 223.11 | 2,042.85 |
| 6 | Tax expense | ||
| 7 | Current tax | 0.00 | 0.00 |
| 8 | Deferred tax | 0.00 | 0.00 |
| 9 | Total tax expenses | 0.00 | 0.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 223.11 | 2,042.85 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 223.11 | 2,042.85 |
| 17 | Other comprehensive income net of taxes | (39.45) | (54.93) |
| 18 | Total Comprehensive Income for the period | 183.66 | 1,987.92 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 5,071.91 | 5,071.91 | |
| Face value of equity share capital | 10 | 10 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 0.44 | 4.03 | |
| Diluted earnings (loss) per share from continuing operations | 0.44 | 4.03 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 0.44 | 4.03 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 0.44 | 4.03 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above results for the quarter and half year ended September 30 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on November 11, 2025. The statutory auditors of the company have expressed a modified conclusion on the Limited review. 2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. 3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. As on September 30, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : Statement of QIP Net Funds raised and utilisation Particulars Amount as stated in Total amount utilised Balance amount as on Remarks the Offer Document upto September 30, 2025 on September 30, 2025 kept Rs. In Lakhs, revised In Lakhs in Fixed Deposits Rs.in lakhs 1. Investment in OBPL, subsidiary, for setting up Jammu Manufacturing Facility 13500 7302 6198 2. Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company 19546 14100 5446 3. Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu 36 36 0 4. General corporate purposes 6098 6372 0 Total 39180 27810 11644 As per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on the proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on September 30, 2025. The allocation among the objects has been revised vide Shareholder Resolution dated September 20, 2025. Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. 4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. 5. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the Company in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, giving No objection to the said amalgamation. The requisite approvals of the concerned shareholders and creditors, as directed, have duly been secured. Further the companies submitted the joint company petition seeking approval on the scheme of Amalgamation, During its hearing held on September 24, 2025, Honble NCLT issued directions to the Office of OffiCial Liquidator and Regional Director to submit their report in the next hearing on November 26, 2025. he Report of Income tax department has already been filed. 6. The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH. Germany and Allecra Therapeutics SAS. France on October 29, 2025 and August 01, 2025 respectively. After the successful completion of above transactions. Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam, International Brand Name known as EXBLIFEP, known as Orblicef in India, consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India back to India. 7. The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH. a Company incorporated under laws of Germany. now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. July 30, 2025. 8. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| Date of start of reporting period | 01-04-2025 | |
| Date of end of reporting period | 30-09-2025 | |
| Whether results are audited or unaudited | Unaudited | |
| Nature of report standalone or consolidated | Standalone | |
| Assets | ||
| 1 | Non-current assets | |
| Property, plant and equipment | 59,495.18 | |
| Capital work-in-progress | 5,447.61 | |
| Investment property | ||
| Goodwill | 0.00 | |
| Other intangible assets | 73.31 | |
| Intangible assets under development | 1,483.17 | |
| Biological assets other than bearer plants | ||
| Investments accounted for using equity method | ||
| Non-current financial assets | ||
| Non-current investments | 6,966.24 | |
| Trade receivables, non-current | ||
| Loans, non-current | 13,130.33 | |
| Other non-current financial assets | 427.53 | |
| Total non-current financial assets | 20,524.10 | |
| Deferred tax assets (net) | 4,871.17 | |
| Other non-current assets | 5,590.22 | |
| Total non-current assets | 97,484.76 | |
| 2 | Current assets | |
| Inventories | 30,622.05 | |
| Current financial asset | ||
| Current investments | 0.00 | |
| Trade receivables, current | 20,217.27 | |
| Cash and cash equivalents | 3,797.46 | |
| Bank balance other than cash and cash equivalents | 9,537.23 | |
| Loans, current | 0.00 | |
| Other current financial assets | 105.75 | |
| Total current financial assets | 33,657.71 | |
| Current tax assets (net) | 191.32 | |
| Other current assets | 3,582.02 | |
| Total current assets | 68,053.10 | |
| 3 | Non-current assets classified as held for sale | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | |
| Total assets | 1,65,537.86 | |
| Equity and liabilities | ||
| 1 | Equity | |
| Equity attributable to owners of parent | ||
| Equity share capital | 5,071.91 | |
| Other equity | 1,29,320.92 | |
| Total equity attributable to owners of parent | 1,34,392.83 | |
| Non controlling interest | ||
| Total equity | 1,34,392.83 | |
| 2 | Liabilities | |
| Non-current liabilities | ||
| Non-current financial liabilities | ||
| Borrowings, non-current | 14,961.94 | |
| Trade payables, non-current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | ||
| Total Trade payable | ||
| Other non-current financial liabilities | ||
| Total non-current financial liabilities | 14,961.94 | |
| Provisions, non-current | 399.59 | |
| Deferred tax liabilities (net) | ||
| Deferred government grants, Non-current | ||
| Other non-current liabilities | 104.87 | |
| Total non-current liabilities | 15,466.40 | |
| Current liabilities | ||
| Current financial liabilities | ||
| Borrowings, current | 4,720.37 | |
| Trade payables, current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 985.85 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 8,580.00 | |
| Total Trade payable | 9,565.85 | |
| Other current financial liabilities | ||
| Total current financial liabilities | 14,286.22 | |
| Other current liabilities | 1,201.84 | |
| Provisions, current | 190.57 | |
| Current tax liabilities (Net) | ||
| Deferred government grants, Current | ||
| Total current liabilities | 15,678.63 | |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | |
| Total liabilities | 31,145.03 | |
| Total equity and liabilites | 1,65,537.86 | |
| Disclosure of notes on assets and liabilities | ||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-07-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 30-09-2025 | 30-09-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Item that will not be reclassified to profit and loss | -3945000 | -5493000 |
| Total Amount of items that will not be reclassified to profit and loss | (39.45) | (54.93) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (39.45) | (54.93) |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 30-09-2025 | ||||
| C | Whether results are audited or unaudited | Unaudited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 2,042.85 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 698.98 | |||||
| Adjustments for decrease (increase) in inventories | 2,015.10 | |||||
| Adjustments for decrease (increase) in trade receivables, current | 4,785.73 | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | 1,262.91 | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 0.00 | |||||
| Adjustments for other financial assets, current | 0.00 | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | (7,488.32) | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 0.00 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 1,744.54 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | (942.37) | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | (0.55) | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | (866.30) | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 1,203.65 | |||||
| Adjustments for share-based payments | 0.00 | |||||
| Adjustments for fair value losses (gains) | 0.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | (839.11) | |||||
| Other adjustments to reconcile profit (loss) | 52.79 | |||||
| Other adjustments for non-cash items | 0.00 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | (780.25) | |||||
| Net cash flows from (used in) operations | 1,262.60 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | (330.55) | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 1,593.15 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 28.95 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 0.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 896.62 | |||||
| Purchase of property, plant and equipment | 6,188.57 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 2,306.01 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 1,380.77 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 5,303.96 | |||||
| Net cash flows from (used in) investing activities | (942.18) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 1,685.49 | |||||
| Repayments of borrowings | 0.00 | |||||
| Payments of lease liabilities | 0.00 | |||||
| Dividends paid | 0.00 | |||||
| Interest paid | 126.08 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | 1,559.41 | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 2,210.38 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0.00 | |||||
| Net increase (decrease) in cash and cash equivalents | 2,210.38 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 1,587.08 | |||||
| Cash and cash equivalents cash flow statement at end of period | 3,797.46 | |||||
| Mode of Fund Raising | QIP |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 27-06-2023 |
| Amount Raised | 40,000.00 |
| Report filed for Quarter ended | 30-09-2025 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | Care Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | Yes |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | Yes |
| If Yes, Date of shareholder Approval | 20-09-2025 |
| Explanation for the Deviation / Variation | In view of changes in the business environment and to meet current strategic requirements, the Company has modified the allocation of the QIP Proceeds. The commencement of “new block at API Facility of the Company in Alathur” project has been postponed to a later stage. Therefore, QIP Proceeds allotted to API Facility in Alathur has been reallocated with the approval of shareholders at the AGM held on September 30, 2025, to mitigate such additional financial burden, improve profit and ensure the best possible utilization of the QIP proceeds in the overall interest of the Company and its shareholders. |
| Comments of the Audit Committee after review | Remark 1: Delay in implementation of the object(s) w.r.t the object- Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu but the extent of delay is not ascertainable. Comment: Alathur project is for further processing of proposed 7ACA into intermediate goods or downstream products from Jammu Project. The Land acquisition for setting up 7ACA project at Jammu is delayed. Consequently, there is delay in setting up of API Facility at Alathur. Hence the major amount remained unutilised. Remark 2: Delay in implementation of the object(s) w.r.t the object- Investment in OBPL for setting up Jammu Manufacturing Facility but the extent of delay is not ascertainable. Comment: The Land of around 203.8 Kanal (25.475 acres) at Jammu had been identified, out of which registration of 164.50 Kanal of land has completed and registration of the remaining land parcel is expect to be completed upto December 2025. Construction of boundary had been completed and construction activity of Major Building is in advance stage. Installation of equipment's already started. The Land acquisition task has been given to Land aggregator who is getting the land from various farmers. Getting the agreement signed from various farmers has taken time. Further for this land Change of Land Use (CLU) / registration was required. This has led to delay in acquiring land. |
| Comments of the auditors, if any | Nil |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | Investment in Orchid Bio Pharma Limited for setting up Manufacturing Facility in Jammu | Not Applicable | 9,000.00 | 13,500.00 | 7,302.00 | 0.00 | The company has transferred Rs. 8.41 crores from MA account to CC account as reimbursement of investment already made in OBPL from its own sources. Further, the Allocation of Rs.45 Crores from Fund raised for API Facility at Alathur. |
| 2 | Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by our Company | Not Applicable | 14,100.00 | 19,546.00 | 14,100.00 | 0.00 | Allocation of Rs.54.46 Crores from Fund raised for API Facility at Alathur. |
| 3 | Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu | Not Applicable | 9,982.00 | 36.00 | 36.00 | 0.00 | Allocated the Funds to other objects of the QIP with the approval of shareholders. |
| 4 | General corporate purposes | Not Applicable | 6,098.00 | 6,098.00 | 6,372.00 | 0.00 | As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and therefore the GCP balance was revised to Rs.6372 Lakhs. |
| Name of signatory | Kapil Dayya |
| Designation of person | Company Secretary and Compliance Officer |
| Place | Gurugram |
| Date | 11-11-2025 |
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Orchid Pharma Limited | Dhanuka Laboratories Limited | Holding Company | Purchase of goods or services | 5,000.00 | Approved | 511.27 | 264.36 | 0.00 | ||||||||||||||||
| 2 | Orchid Pharma Limited | Dhanuka Laboratories Limited | Holding Company | Any other transaction | Lease Rent Received | 250.00 | Approved | 45.86 | 14.56 | 0.00 | |||||||||||||||
| 3 | Orchid Pharma Limited | Dhanuka Laboratories Limited | Holding Company | Sale of goods or services | 5,000.00 | Approved | 144.23 | 131.54 | 113.45 | ||||||||||||||||
| 4 | Orchid Pharma Limited | DHANUKA AGRITECH LIMITED | Related Party under sec2(76)(1v) of Companies Act, 2013 | Any other transaction | lease rents paid | 150.00 | Approved | 23.44 | 13.73 | 0.00 | |||||||||||||||
| 5 | Orchid Pharma Limited | DHANUKA AGRITECH LIMITED | Related Party under sec2(76)(1v) of Companies Act, 2013 | Any other transaction | Reimbursement of expenses | Not Applicable | 1.73 | 0.00 | 0.00 | ||||||||||||||||
| 6 | Orchid Pharma Limited | DHANUKA AGRITECH LIMITED | Related Party under sec2(76)(1v) of Companies Act, 2013 | Any other transaction | rental deposit paid | Approved | 0.00 | 19.10 | 19.10 | ||||||||||||||||
| 7 | Orchid Pharma Limited | ORBION PHARMACEUTICALS PRIVATE LIMITED | Associate Company | Sale of goods or services | 500.00 | Approved | 0.00 | 0.17 | 0.00 | ||||||||||||||||
| 8 | Orchid Pharma Limited | ORCHID BIO-PHARMA LIMITED | Subsidiary Company | Loan | 35,000.00 | Approved | 1,586.56 | 10,824.32 | 13,130.33 | Loan | 12.00 | Payable on Demand but not prior to closure of Fiunding/Loans availed from Schdeuled Commercial Banks by OBPL for setting up the Project | Unsecured | For investing in capital project | |||||||||||
| 9 | Orchid Pharma Limited | ORCHID BIO-PHARMA LIMITED | Subsidiary Company | Interest received | 4,000.00 | Approved | 719.45 | 0.00 | 0.00 | ||||||||||||||||
| 10 | Orchid Pharma Limited | ORCHID BIO-PHARMA LIMITED | Subsidiary Company | Any other transaction | corporate gaurantee commission received | 600.00 | Approved | 126.21 | 0.00 | 0.00 | |||||||||||||||
| 11 | Orchid Pharma Limited | OTSUKA CHEMICAL (INDIA) PVT LTD | Related Party under Section 2(76)(iii) of the Companies Act,2013 | Purchase of goods or services | 40,000.00 | Approved | 5,432.45 | 5,782.78 | 983.07 | ||||||||||||||||
| 12 | Orchid Pharma Limited | Synmedic Laboratories | Related Party under Section 2(76)(iii) of the Companies Act,2013 | Purchase of goods or services | 100.00 | Approved | 0.03 | 0.00 | 0.01 | ||||||||||||||||
| 13 | Orchid Pharma Limited | Synmedic Laboratories | Related Party under Section 2(76)(iii) of the Companies Act,2013 | Sale of goods or services | 500.00 | Approved | 7.02 | 21.40 | 7.02 | ||||||||||||||||
| 14 | Orchid Pharma Limited | Synmedic Laboratories | Related Party under Section 2(76)(iii) of the Companies Act,2013 | Any other transaction | Lease Rent received | 200.00 | Approved | 31.22 | 0.00 | 0.00 | |||||||||||||||
| 15 | Orchid Pharma Limited | ORCHID BIO-PHARMA LIMITED | Subsidiary Company | Any other transaction | Corporate Guarantee issued on behalf of Orchid Bio-Pharma Ltd | Not Applicable | 1,337.00 | 0.00 | 0.00 | ||||||||||||||||
| Total value of transaction during the reporting period | 9,966.47 | ||||||||||||||||||||||||